CNR1 and metabolic syndrome: Additional research of asprosin regulation in an obesity model of monosodium glutamate (MSG)-induced hypothalamic obesity mice showed that 3-weeks treatment by AM6545, a peripheral cannabinoid receptor 1 (CB1R) blocker, diminishes the level of asprosin while reducing the increased body weight, dyslipidemia and intraperitoneal fat mass (Ma et al., 2018).